News Related to MDS-Associated Anemia

Related coverage linked through entity extraction aliases.

Bristol Myers Squibb leans on growth portfolio as legacy drugs face 2026 pressure

Apr 11, 2026

Bristol Myers Squibb said 2025 revenue was flat as a 17% increase in growth-portfolio sales offset a 15% decline in legacy drugs. The company expects legacy sales to fall another 12-16% in 2026, with newer products such as Opdivo, Reblozyl and Breyanzi supporting results.

Bristol Myers Squibb Growth Portfolio Offsets Legacy Drug Declines in 2025

Mar 03, 2026

Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.